Antipsychotic drugs in schizophrenia: current issues

Area of Science:

• Pharmacology
• Psychiatry
• Neuroscience

Background:

• Antipsychotic antidopaminergic drugs have been the cornerstone of schizophrenia treatment since the 1950s.
• Significant knowledge has accumulated, yet critical issues remain inadequately addressed in existing literature.

Purpose of the Study:

• To review and critically analyze unresolved issues concerning antipsychotic medications in schizophrenia management.
• To focus on factors previously resolved inadequately in prior studies.

Main Methods:

• Literature review focusing on optimal antipsychotic dosages across different schizophrenia phases (rapid tranquilization, acute, chronic, maintenance).
• Discussion of plasma neuroleptic level measurement methodologies, their limitations, and correlations with treatment outcomes for specific drugs (chlorpromazine, haloperidol, fluphenazine).
• Review of research on supersensitivity psychosis, atypical neuroleptics' dopamine receptor selectivity, and unorthodox clinical strategies.

Main Results:

• Analysis of optimal dosing strategies for various schizophrenia treatment phases.
• Evaluation of plasma level monitoring techniques and their correlation with efficacy and side effects.
• Critique of supersensitivity psychosis concept and review of atypical neuroleptic receptor selectivity.

Conclusions:

• Optimal antipsychotic dosing and plasma level monitoring require further refinement.
• The concept of supersensitivity psychosis needs critical re-evaluation.
• Emerging research on atypical neuroleptics and novel strategies offers potential for improved schizophrenia management.